Current Emergency and Hospital Medicine Reports

, Volume 6, Issue 3, pp 94–100 | Cite as

Select Advances in Infectious Disease Chemotherapy: Review for Emergency Department Practitioners

  • Boris GarberEmail author
  • Jonathan Glauser
  • Sarah Money
Infectious Disease (J Glauser, Section Editor)
Part of the following topical collections:
  1. Infectious Disease


Purpose of Review

We provide an overview of new chemotherapy agents for the treatment of bacterial, viral, fungal, and parasitic infections with indications, contraindications, and side effects for each. Some of them have been restricted for use only by subspecialists, possibly limiting emergency physicians’ comfort with prescribing these medications. We also review some new and promising agents that have not been approved by the Food and Drug Administration as of this writing.

Recent Findings

As new antibiotics are approved and widely used, postmarketing surveys uncover important findings with respect to the drugs’ efficacy, drug interactions, and side effects. The fact that these agents are intended to definitively cure diseases which may in some cases prove lethal makes it imperative for clinicians to stay abreast of developments in infectious disease. Conversely, the fact that these medications are prescribed for limited periods of time in order to prove curative and to prevent the development of resistance poses financial challenges to the pharmaceutical industry.


This article provides the emergency department clinicians with a summary of novel antimicrobials and their relevance to the practice of clinical and emergency medicine, as well as highlighting recent research into the topic.


Antimicrobials Emergency care Novel antibiotics Antibiotic resistance Antivirals Antifungals 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. 1.
    •• Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J Antibiot. 2016;69:73–88. Gives rationale for why pharmaceutical companies may be lagging in funding for newer antibacterials. CrossRefPubMedGoogle Scholar
  2. 2.
    Arias CA, Murray BE. A new antibiotic and the evolution of resistance. N Engl J Med. 2015;372:1168–70.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bassetti M, Righi E. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Curr Opin Crit Care. 2015;21(5):402–11.CrossRefPubMedGoogle Scholar
  4. 4.
    Falzon, D., Schünemann, H. J. (2017). World Health Organization treatment guidelines for drug-resistant tuberculosis 2016 Update Eur Respir J, 49, 3.Google Scholar
  5. 5.
    Roca M, Akova F, Baquero, et al. The global threat of antimicrobial resistance: science for intervention. New Microb New Infect. 2015, July;6:22–9.CrossRefGoogle Scholar
  6. 6.
    McCullough AR, Parekh S, Rathbone J, et al. A systematic review of the public’s knowledge and beliefs about antibiotic resistance. J Antimicrob Chemother. 2016;71(1):27–33.CrossRefPubMedGoogle Scholar
  7. 7.
    Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot. 2013;66:571–91.CrossRefPubMedGoogle Scholar
  8. 8.
    • Czaplewski L, Bax R, et al. Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis. 2016;16(2):239–51. Lists alternative methods by which infectious disease may be combatted. CrossRefPubMedGoogle Scholar
  9. 9.
    Younis W, Thangamani S, et al. Repurposing non-antimicrobial drugs and clinical molecules to treat bacterial infections. Curr Pharm Des. 2015;21(28):4106–11.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kaye KS, Gales AC, Dubourg G. Old antibiotics for multidrug-resistant pathogens: from in vitro activity to clinical outcomes. Int J Antimicrob Agents. 2017;49(5):542–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Abbas M, et al. New and improved? A review of novel antibiotics for gram-positive bacteria. Clin Microbiol Infect. 2017;23(10):697–703.CrossRefPubMedGoogle Scholar
  12. 12.
    Bassères E, Endres BT, et al. Novel antibiotics in development to treat clostridium difficile infection. Curr Opin Gastroenterol. 2017;33(1):1–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Van Hal SJ, Paterson DL. New gram-positive antibiotics: better than vancomycin? Curr Opin Infect Dis. 2011;24(6):515–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Hancock RE. Mechanisms of action of newer antibiotics for gram-positive pathogens. Lancet Infect Dis. 2005;5(4):209–18.CrossRefPubMedGoogle Scholar
  15. 15.
    Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with gram-negative bacteria: restoring the miracle or false Dawn? Clin Microbiol Infect. 2017;23(10):704–12.CrossRefPubMedGoogle Scholar
  16. 16.
    • Ambrose PG, Lomovskaya O, et al. β-Lactamase inhibitors: what you really need to know. Curr Opin Pharmacol. 2017;36:86–93. Discusses the mechanisms by which organisms develop resistance. CrossRefPubMedGoogle Scholar
  17. 17.
    DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharm Ther. 2009;87:272–7.CrossRefGoogle Scholar
  18. 18.
    Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10 x ‘20 progress—development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1685–94.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Nathan C, Cars O. Antibiotic resistance—problems, progress, and prospects. N Engl J Med. 2014;371:1761–3.CrossRefPubMedGoogle Scholar
  20. 20.
    Laidman J. Despite growing crisis, few new antibiotics are in pipeline. Medscape Med News. 2013Google Scholar
  21. 21.
    Outterson K, Powers JH, Daniel GW, McClellan MB. Repairing the broken market for antibiotic innovation. Health Aff. 2015;34:277–85.CrossRefGoogle Scholar
  22. 22.
    Delafloxacin: a new fluoroquinolone antibiotic. Med Lett Drugs Ther. 2018;60(1543):49–51.Google Scholar
  23. 23.
    •• Drugs for common bacterial infections in adults. Med Lett Drugs Ther. 2017;59(1532):171–7. This is an overview of treatment for specific bacterial diseases. This is an authoritative publication with recommendations made generally by panels held in high esteem. Google Scholar
  24. 24.
    Available at -Drugs Accessed 25 April 2018.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.MetroHealth Medical CenterCase Western Reserve UniversityClevelandUSA
  2. 2.Case Western Reserve UniversityClevelandUSA
  3. 3.Spine InstituteUniversity of MichiganAnn ArborUSA

Personalised recommendations